

# *Lycium barbarum* polysaccharides regulate phenotypic and functional maturation of murine dendritic cells

Jie Zhu<sup>a</sup>, Lu-Hang Zhao<sup>a,b,\*</sup>, Xiao-Ping Zhao<sup>c</sup>, Zhi Chen<sup>b</sup>

<sup>a</sup> Department of Biochemistry and Molecular Biology, College of Medicine, Zhejiang University, Hangzhou 310006, Republic of China

<sup>b</sup> Experimental Center for molecule and cell biology, College of Medicine, Zhejiang University, Hangzhou 310006, Republic of China

<sup>c</sup> Zhejiang Medical College, Hangzhou 310053, Republic of China

Received 9 March 2006; revised 19 November 2006; accepted 15 December 2006

## Abstract

*Lycium barbarum* polysaccharides (LBPs) have been known to have a variety of immunomodulatory functions including activation of T cells, B cells and NK cells. Dendritic cells (DC) are potent antigen-presenting cells that play pivotal roles in the initiation of the primary immune response. However, little is known about the immunomodulatory effects of LBPs on murine bone marrow derived dendritic cells (BMDC). In the present study, the effects of LBPs on the phenotypic and functional maturation of murine BMDC were investigated *in vitro*. Compared to the BMDC that were only subjected to treatment with RPMI1640, the co-expression of I-A/I-E, CD11c and secretion of IL-12 p40 by BMDC stimulated with LBPs (100 µg/ml) were increased. In addition, the endocytosis of FITC-dextran by LBPs-treated BMDC (100 µg/ml) was impaired, whereas the activation of proliferation of allogenic lymphocytes by BMDC was enhanced. Our results strongly suggest that LBPs are capable of promoting both the phenotypic and functional maturation of murine BMDC *in vitro*.

© 2007 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.

**Keywords:** *Lycium barbarum* polysaccharides (LBPs); Dendritic cells (DC); Mixed lymphocyte reaction (MLR)

## 1. Introduction

*Lycium barbarum*, a well-known Chinese traditional medicine and also an edible food, plays multiple roles in pharmacological and biological functions including anti-aging activity, hypoglycemic and hypolipidemic effects, strengthening yang and improving eyesight. It has been reported that polysaccharides purified from *Lycium barbarum* are especially effective in modulating immune functions and inhibiting tumor growth (Gong et al., 2005; Gan et al., 2004; Cao et al., 1994). The immuno-modulation effects of LBPs are extensive, including increasing macrophage phagocytosis, the form of antibody secreted by spleen cells, spleen lymphocyte proliferation and

CTL activity. Recently, the antitumor effects of LBPs have been investigated and are believed to be going through immune mechanisms (Gan et al., 2003, 2004).

DC, one of the most potent antigen-presenting cells (APC), are important for the initiation of primary immune response of both helper and cytotoxic T lymphocytes (Banchereua et al., 2000; Banchereua and Steinman, 1998; Lanzavecchia and Sallusto, 2001; Liu, 2001). After antigen capture, the DC precursors migrate to T cell regions of draining lymph nodes where they mature into functional DC. The functional DC further stimulate naive T cells by triggering the signaling pathway involving both major histocompatibility complex (MHC) molecules presenting antigen-peptides and co-stimulatory molecules (Austyn et al., 1988; Rock, 1996). The initial contact between DC and resting T cells may be mediated by a transient, high affinity interaction between DC-SIGN on the DC and the adhesion molecule ICAM-3 on the T cells (Geijtenbeek et al., 2000), followed by interactions through other adhesion molecules and their corresponding ligands (ICAM-1/LFA-1,

\* Corresponding author. Department of Biochemistry and Molecular Biology, College of Medicine, Zhejiang University, Hangzhou 310006, Republic of China. Tel./fax: +86 571 8721 7415.

E-mail address: zhaoluhang@263.net (L.-H. Zhao).

LFA-1/CD2). Following TCR engagement, an intimate interaction often referred to as the immunological synapse evolves, where multiple interactions between co-stimulatory molecules on DC and their ligands on T cells result in final DC maturation and T cell activation (Banchereau et al., 2000; Lanzavecchia and Sallusto, 2000). There are no reports about LBPs inducing maturation of murine BMDC. Therefore, LBPs regulating phenotypic and functional maturation of murine BMDC were investigated in this study.

## 2. Materials and methods

### 2.1. Source of mice

Male or female C57BL/6J (H-2<sup>b</sup>) and BALB/c (H-2<sup>d</sup>) mice were purchased from the Department of Experimental Animal, College of Medicine, Zhejiang University, Hangzhou, China. Mice were used at 4–6 weeks of age.

### 2.2. Source of drugs

LBPs were purchased from Pharmagenesis Beijing Office. The percentage of polysaccharide of LBPs was about 84.32% according to the phenol-sulfuric acid colorimetric method. The molecular weights of LBPs were estimated to be 31,000 through high performance gel filtration chromatography. The LBPs mainly consist of mannose, glucose, galactose, arabinose, rhamnose and xylose.

### 2.3. Generation of bone marrow-derived murine myeloid DC

DC were prepared as described previously with minor modifications (Inaba et al., 1992). Briefly, bone marrow cells were flushed from the femur and tibiae of C57BL/6J mice and depleted of RBC by hypotonic lysis using Tris-NH<sub>4</sub>Cl. Cells with a starting number of  $2 \times 10^6$  cells per ml were cultured in RPMI 1640 in six-well flat bottom plates (Orange Scientific) at 37 °C, 5% CO<sub>2</sub>, supplemented with 10% fetal calf serum (FCS), 2 mmol/l L-glutamine, 100 U/ml penicillin G, 100 µg/ml streptomycin, 30 ng/ml rmGM-CSF (Peprotech) and 20 ng/ml rmIL-4 (Peprotech). On day 3, the old medium was replaced with fresh medium. On day 5, cells were purified by MACS columns (Miltenyi Biotec). CD11c<sup>+</sup> DC were acquired and divided into 3 groups. In parallel, 3 groups of DC were incubated at a concentration of  $1 \times 10^5$ /ml with either 100 µg/ml LBPs, serum-free RPMI media 1640 or 100 ng/ml LPS (serotype 0111:24; Sigma). The serum-free RPMI media 1640 and 100 ng/ml LPS groups were used as controls. On day 7, cells and culture supernatants were collected for further experiments and analysis.

### 2.4. Flow cytometric analysis

Cell surface expression of I-A/I-E or CD11c was determined by immunofluorescence staining. On day 7, cells were harvested, washed twice with PBS, and resuspended in washing buffer (PBS containing 2% FCS and 0.1% sodium azide). Cells were first blocked with 20% mixed mouse and rat serum for 15 min at 4 °C, and then stained with PE conjugated anti-mouse I-A/I-E antibody (BD Pharmingen) and FITC conjugated anti-mouse CD11c antibody (BD Pharmingen) for 30 min at 4 °C in the dark. Lastly the antibody-treated cells were washed twice with washing buffer. Cell surface co-expression of I-A/I-E and CD11c was detected by flow cytometry (Becton Dickinson). All the obtained data were analyzed by the CellQuest software package.

### 2.5. Cytokine assay

On day 7, DC culture supernatants were collected and the concentration of mouse IL-12 p40 unit was determined by a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Biosource) according to the manufacturer's

instructions. Cytokine concentrations were determined according to absorbance readings at 450 nm on a universal microplate reader (Bio-Tek Instruments).

### 2.6. Endocytosis assay

In order to analyze the endocytic capacity of DC on day 7,  $1 \times 10^5$  cells were incubated at 37 °C for 1 h with 1 mg/ml FITC-dextran (Sigma). In the parallel experiment  $1 \times 10^5$  cells were incubated at 4 °C for 1 h. After incubation, the cells were washed twice with cold HBSS. The cells were analyzed on a flow cytometer.

### 2.7. Mixed lymphocyte reaction (MLR) induced by DC

Responder mononuclear lymphocytes from H-2<sup>d</sup> BALB/c's splenocytes were isolated by Ficoll-Urografin density gradient. On day 7, mature DC were harvested as inducers, treated with 25 µg/ml mitomycin C (AppliChem) for 45 min, then  $5 \times 10^3$  cells were added to allogeneic lymphocytes ( $1 \times 10^5$  cells per well) in flat-bottom 96-well tissue culture plates for 120 h. Cell proliferation was estimated according to the cellular reduction of tetrazolium salt MTT (Sangon) by the mitochondrial dehydrogenase of viable cells into a blue formazan product that was measured spectrophotometrically.

### 2.8. Statistics

The results were expressed as means  $\pm$  SD of the indicated number of experiments. The statistical significance was estimated using a Student's *t*-test for unpaired observations. A *p* value of <0.05 was considered to be significant.

## 3. Results

### 3.1. LBPs up-regulate the co-expression of I-A/I-E and CD11c on DC surface

LBPs (100 µg/ml) or LPS (100 ng/ml) treated DC showed an increased co-expression of I-A/I-E and CD11c on DC surface, and the double positive cells ratio were  $(41.42 \pm 1.43)\%$  or  $(54.13 \pm 3.99)\%$ , respectively, whereas that of RPMI 1640 was  $(35.68 \pm 2.40)\%$ . The difference was significant by paired *t* test analysis:  $n = 4$ ,  $P < 0.01$ ). One groups' figure of flow cytometric analysis is shown (Fig. 1).

### 3.2. LBPs increase IL-12 p40 production of DC

LBPs (100 µg/ml) or LPS (100 ng/ml) treated DC showed an increased production of IL-12 p40 in culture supernatants of DC, and the production was  $94.1 \pm 12.2$  pg/ml,  $263.6 \pm 13.8$  pg/ml, respectively, compared with  $57.3 \pm 17.2$  pg/ml of RPMI 1640. A significant difference was observed between RPMI 1640 control and 100 µg/ml LBPs group or LPS group (Fig. 2). The difference was significant by paired *t* test analysis:  $n = 4$ ,  $P < 0.01$ ).

### 3.3. LBPs inhibit the FITC-dextran uptake by DC

Mannose-receptor-mediated endocytosis was analyzed by the uptake of FITC-dextran. In DC treated by LBPs (100 µg/ml) or LPS (100 ng/ml), the percentage  $(30.96 \pm 3.30)$  and  $19.66 \pm 2.01$ , respectively) of FITC-stained cells had a significantly lower uptake of FITC-dextran, compared with RPMI 1640  $(68.52 \pm 1.66)\%$ . Parallel experiments were also




Fig. 1. Flow cytometric analysis of DC treated with RPMI 1640, LBPs or LPS. On day 5 of DC culture, cells were incubated at a concentration of  $1 \times 10^5$  per well with 100 ng/ml LPS and 100  $\mu$ g/ml LBPs. Serum-free RPMI 1640 was used as control. On day 7, cells were stained with R-PE conjugated anti-mouse I-A/I-E and FITC conjugated anti-mouse CD11c for 30 min at 4 °C in the dark. Fluorescence profiles were generated on a FACS flow cytometer. Histogram and density plots were produced by CellQuest software package. FL1-H: FITC conjugated anti-mouse CD11c; FL2-H: R-PE conjugated anti-mouse I-A/I-E.

performed at 4 °C ( $15.93 \pm 1.02$ ), FITC-dextran was internalized significantly less than DC at 37 °C. The difference was significant by paired *t* test analysis:  $n = 4$ ,  $P < 0.01$ ). One groups' figure of flow cytometric analysis is shown (Fig. 3).

### 3.4. LBPs facilitate the allostimulatory capacity of DC

The effects of LBPs on MLR induced by DC are illustrated in Fig. 4. LBPs (100  $\mu$ g/ml)-treated DC or LPS (100 ng/ml)-treated DC stimulated proliferative responses more effectively than RPMI 1640-treated DC, and the proliferation ratio of the lymphocytes was ( $129.9 \pm 12.48$ )% or ( $153.8 \pm 14.15$ )%, respectively, compared with ( $100 \pm 9.12$ )% of RPMI 1640 (Fig. 2). The difference was significant by paired *t* test analysis:  $n = 5$ ,  $P < 0.05$ ). (RPMI 1640 control served as 100%).

## 4. Discussion

It has been well-known for decades that LBPs are biologically active components of *Lycium barbarum* with potential pharmacological and biological functions. This is the first report that we are aware of showing the effects of LBPs on the generation and maturation of murine BMDC. In this study, we have shown that LBPs can induce maturation of murine BMDC and ready them for T cell-mediated immune responses. LBPs significantly increase the expression of membrane molecules I-A/I-E and CD11c. Meanwhile, LBPs markedly reduce the endocytic activity of DC and augment their capacity to promote the proliferation of naïve allogeneic T cells.

DC can differentiate from immature to mature stages by various stimulators, by cytokines such as TNF- $\alpha$  or pathogen products, or LPS (Banchereua et al., 2000). Immature DC have a high capacity for antigen capture and processing. Maturation of DC are characterized by a decreased antigen processing capacity, an increased cell surface expression of

MHC and co-stimulatory molecules, and the secretion of IL-12, priming strong stimulation of CD4<sup>+</sup> and CD8<sup>+</sup>T lymphocyte growth and differentiation (Banchereua et al., 2000; Banchereau and Steinman, 1998; Lanzavecchia and Sallusto, 2001). Mature DC can secrete IL-12 p70, the active protein, and then prime Th1 lymphocyte transformation. IL-12 p40 is a subunit of IL-12 p70, whose expression is inducible and correlated with the production of bioactive IL-12 p70 by DC; while another subunit, IL-12 p35, is encoded on separate genes and constitutively expressed by a variety of cell types (Schoenhaut et al., 1992; Trinchieri, 1995). Our data indicate that exposure to LBPs increase the production of bioactive IL-12 p70 in murine BMDC in the presence of GM-CSF/IL-4.




Fig. 2. Production of IL-12 p40 in culture supernatants of DC treated with RPMI 1640, LBPs or LPS. On day 5 of DC culture, cells were incubated at a concentration  $1 \times 10^5$  per well with 100 ng/ml LPS and 100  $\mu$ g/ml LBPs. RPMI 1640 was used as control. On day 7, culture supernatants were collected for detecting the level of mouse IL-12 P40 (by ELISA). Cytokine concentration was determined with a standard curve derived from known amounts of the IL-12 P40.  $n = 4$ ,  $*P < 0.01$  vs. RPMI 1640.




Fig. 3. Antigen uptake by DC stimulated by RPMI 1640, LBPs or LPS. On day 5 of DC culture, cells were incubated at a concentration of  $1 \times 10^5$  per well with 100 ng/ml LPS and 100  $\mu$ g/ml LBPs. On day 7, after cells were collected, the endocytic activity of the DC was determined by flow cytometry after treatment with FITC-dextran. Thereafter, the cells were washed twice with cold HBSS. The control endocytic activity was determined after FITC-dextran treatment at 4 °C. Data represents the percentages of cells.

Also, we investigated the capacity of LBPs-treated DC to internalize FITC-dextran via mannose receptor-mediated endocytosis. Both mechanisms are complex, energy-dependant processes that require the coordinated action of the actin cytoskeleton and are characteristic and distinctive properties of immature vs. mature DC (Sallusto et al., 1995; Garrett and Mellmann, 1999). These data further support the view that exposure to LBPs promotes the generation of functionally active, mature DC.

It is well-known that tumors are sources of biological substances and release certain immunosuppressive factors to evade the immune surveillance system of the host (Kanto et al., 2001). Through analysis of tumor specimens obtained from patients, a reduced number of DC infiltrated into tumors correlated with a poor prognosis for patients (Zeid and Muller, 1993; Tsuge et al., 2000). Also, the phenotypes and function of DC could be altered in tumors. The reduction of expression of co-stimulatory molecules, defective cytokine production, and full allostimulatory activity could be found in DC infiltrated into tumor tissue, which implies that tumor-derived

factors can impede DC maturation (Gabrilovich et al., 1997; Troy et al., 1998). These effects appear to be maturation-dependent, acting only on DC precursors and not mature DC. Therefore, it may be better to use mature DC for clinical applications.

LBPs as a traditional Chinese herb have been extensively used in improving the immune activity of patients treated by chemical or radiation therapy. According to the results of this study, LBPs enhance the phenotypic and functional maturation of DC. Therefore, LBPs may increase the antitumor effects of DC-based vaccine therapy. Now we are investigating the antitumor effects of a combination therapy through an LBPs- and DC-based vaccine in a tumor-bearing mouse model.

## Acknowledgments

We sincerely thank Mr. Janping Pan for his excellent technical and theoretical assistance.

## References

- Austyn JM, Kupiec-Weglinski JW, Hankins DF, Morris PJ. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. *J Exp Med* 1988;167: 646–51.
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* 1998;392:245–52.
- Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. *Annu Rev Immunol* 2000;18:767–811.
- Cao GW, Yang WG, Du P. Observation of the effects of LAK/IL-2 therapy combining with *Lycium barbarum* polysaccharides in the treatment of 75 cancer patients. *Zhonghua Zhong Liu Za Zhi* 1994;16:428–31.
- Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. *Clin Cancer Res* 1997;3:483–90.
- Gan L, Zhang SH, Liu Q, Xu HB. A polysaccharide-protein complex from *Lycium barbarum* upregulates cytokine expression in human peripheral blood mononuclear cells. *Eur J Pharmacol* 2003;3:217–22.
- Gan L, Hua ZS, Liang YX, Bi XH. Immunomodulation and antitumor activity by a polysaccharide-protein complex from *Lycium barbarum*. *Int Immunopharmacol* 2004;4:563–9.
- Garrett WS, Mellmann I. Studies of endocytosis. In: Lotze MT, Thomson AW, editors. *Dendritic Cells*. San Diego: Academic Press; 1999. p. 693.




Fig. 4. Lymphocyte proliferation of MLR induced by DC. On day 5 of DC culture, cells were incubated with 100 ng/ml LPS and 100  $\mu$ g/ml LBPs. RPMI 1640 was used as control. On day 7, mature DC was treated with 25  $\mu$ g/ml mitomycin C and mononuclear lymphocytes from splenocytes were isolated by Ficoll-Urografin density gradient. H-2<sup>d</sup> BABL/c responder spleen lymphocytes ( $1 \times 10^5$  cells per well) were cultured with H-2<sup>b</sup> C57BL/6j inducer mature LBPs-treated DC, RPMI 1640-treated DC or LPS-treated DC (all at  $5 \times 10^3$  cells per well). Cell proliferation was estimated by MTT method.  $n = 5$ , \* $P < 0.05$  vs. RPMI 1640.

- Geijtenbeek TH, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell* 2000;100:575–85.
- Gong H, Shen P, Jin L, Xing C, Tang F. Therapeutic effects of *Lycium barbarum* polysaccharide (LBP) on irradiation or chemotherapy-induced myelosuppressive mice. *Cancer Biother Radiopharm* 2005;20:155–62.
- Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1992;176:1693–702.
- Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscatto AA. Ceramide mediates tumor-induced dendritic cell apoptosis. *J Immunol* 2001;167:3773–84.
- Lanzavecchia A, Sallusto F. From synapses to immunological memory: the role of sustained T cell stimulation. *Curr Opin Immunol* 2000;12:92–8.
- Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. *Cell* 2001;106:263–6.
- Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. *Cell* 2001;106:259–62.
- Rock KL. A new foreign policy: MHC class molecules monitor the outside world. *Immunol Today* 1996;17:131–7.
- Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells used macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. *J Exp Med* 1995;182:389–400.
- Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, et al. Cloning and expression of murine IL-12. *J Immunol* 1992;148:3433–40.
- Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu Rev Immunol* 1995;13:251–76.
- Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. *Clin Cancer Res* 1998;4:585–93.
- Tsuge T, Yamakawa M, Tsukamoto M. Infiltrating dendritic/Langerhans cells in primary breast cancer. *Breast Cancer Res Treat* 2000;59:141–52.
- Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. *Pathology* 1993;25:338–43.